Hemophilia Supportive Care Protocol

Hemophilia is a genetic bleeding disorder caused by deficiency of clotting factors (Factor VIII in Hemophilia A, Factor IX in Hemophilia B). This results in prolonged bleeding, especially into joints (hemarthrosis) and muscles. Without treatment, repeated joint bleeds lead to hemophilic arthropathy (chronic joint damage). Modern treatment with factor replacement or newer non-factor therapies (emicizumab) has transformed outcomes.

CRITICAL: Hemophilia requires lifelong management by a specialized hemophilia treatment center. Primary treatment includes:

•Factor replacement therapy: On-demand (for bleeds) or prophylactic (regular infusions to prevent bleeds)

•Non-factor therapies: Emicizumab (Hemlibra) for hemophilia A; other agents in development

•Gene therapy: Emerging curative option for some patients

•Physical therapy: Essential for joint health

•Bleed management protocol: Know when and how to treat bleeds

SUPPLEMENTS TO AVOID OR USE WITH CAUTION:

•Fish oil at high doses may slightly increase bleeding risk

•Vitamin E at high doses may increase bleeding

•Garlic supplements may increase bleeding

•Ginkgo biloba may increase bleeding

•NSAIDs (not a supplement but commonly used) should be avoided

SUPPORTIVE SUPPLEMENTS:

* Vitamin D and Calcium are important because hemophilia patients have significantly higher rates of osteoporosis (up to 70% have low bone density). This is due to limited weight-bearing exercise and chronic joint disease.

* Iron may be needed if chronic bleeding causes iron deficiency. Always test before supplementing.

* Glucosamine/Chondroitin may support joint health, which is the major long-term issue in hemophilia.

* Omega-3s (moderate dose) may help with joint inflammation, but use cautiously and discuss with your hematologist.

Expected outcomes: Supplements support overall health but do not replace factor therapy or hemophilia treatment. Work closely with your hemophilia treatment center.

Clinical Perspective

Hemophilia: X-linked recessive bleeding disorders. Hemophilia A: Factor VIII deficiency (~80% of cases); Hemophilia B (Christmas disease): Factor IX deficiency (~20%). Severity: Severe (<1% factor activity), Moderate (1-5%), Mild (5-40%). Inheritance: X-linked; males affected; females carriers (may have mild symptoms). Complications: hemarthrosis (joint bleeds) → hemophilic arthropathy; muscle bleeds; inhibitor development (antibodies against replacement factor).

CRITICAL: Hemophilia Treatment Center (HTC) management essential. Treatment: Factor replacement (on-demand or prophylaxis); extended half-life products; non-factor therapies (emicizumab for Hemo A); gene therapy (FDA-approved options emerging). Inhibitors: major complication - immune tolerance induction, bypassing agents. Avoid anticoagulants, antiplatelet agents, NSAIDs, IM injections. Exercise important but avoid contact sports. Supplements are SUPPORTIVE - coordinate with hematology team.

* Vitamin D (B-grade): Bone health critical - up to 70% have osteoporosis/osteopenia. Systematic review: bone health (PMID: 27622672). Study: deficiency (PMID: 28132425). 2000-4000 IU daily; target >40 ng/mL.

* Calcium (B-grade): Bone health with vitamin D. Review: (PMID: 27622672). 1000-1200mg daily.

* Iron (B-grade): If chronic blood loss/deficiency. Review: (PMID: 28339170). Test first; supplement if deficient.

* Omega-3 Fatty Acids (C-grade): Joint inflammation; use moderate doses. Review: joint health (PMID: 27837121). 1-2g EPA+DHA daily. Minimal bleeding effect at this dose but discuss with hematologist.

* Glucosamine/Chondroitin (C-grade): Joint support. Review: (PMID: 20847017). 1500mg/1200mg daily.

* Vitamin C (C-grade): Collagen; connective tissue. Review: (PMID: 23075608). 500-1000mg daily.

* Vitamin B12 (C-grade): RBC production. Review: (PMID: 28660890). 500-1000mcg daily.

* Folate (C-grade): RBC production. Review: (PMID: 28403564). 400-800mcg daily.

* Probiotics (C-grade): GI health. Systematic review: (PMID: 27231050). 10-20 billion CFU daily.

Assessment targets: Factor levels, inhibitor screening, joint health scores (HJHS), bone density (DEXA), iron studies, bleed frequency, quality of life.

Protocol notes: Bone health: DEXA recommended periodically; weight-bearing exercise (when safe) important; bisphosphonates if osteoporosis. Joint health: physical therapy essential; synovitis prevention; joint replacement if severe arthropathy. Prophylaxis: standard of care for severe hemophilia - prevents joint damage; extended half-life products allow less frequent dosing. Emicizumab: bispecific antibody mimicking Factor VIII function; subcutaneous; weekly to monthly dosing; game-changer for Hemo A. Gene therapy: valoctocogene roxaparvovec (Roctavian) for Hemo A; etranacogene dezaparvovec (Hemgenix) for Hemo B - single infusion may provide years of factor production. Inhibitors: develop in ~30% severe Hemo A; treatment challenging; immune tolerance induction, bypassing agents. Avoid: IM injections, contact sports, NSAIDs, aspirin. Safe exercise: swimming, walking, cycling (with proper protection). Dental care: important - consult HTC before procedures. Vaccinations: may need factor cover for some; subcutaneous route preferred. Hepatitis C: historical risk from blood products; newer patients don't have this exposure. HIV: historical risk; current products safe. Carriers: female carriers may have reduced factor levels and bleeding symptoms - should be tested.

View All Protocols